Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation
Which stocks are undervalued right now? Check free
Discover now →
Bachem Holding (BCHMF) fair value: what the stock is really worth
As of Sep 25, 2026: fair value of Bachem Holding $33.77, price $91.00, upside -62.9%, quality 57 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.
- Fair value above price? No
- Good quality? Yes
- Add to watchlist
BH
Broad data
Sep 23, 2026
Broad data
Sep 23, 2026
Bachem Holding
BCHMF · USStretched ValuationStrong overvaluation with only moderate quality.
!Fair value $33.77 · Strongly overvalued (−62.9%)
!Quality 57/100
!Expensive Growth (revenue 5y +11.6 %/yr)
✓Highly profitable · 21.4% net margin (TTM)
!Low debt · negative free cash flow
!1.0% dividend yield · Token dividend
✓Wide moat 65/100
Watch Bachem Holding for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.
Watch for free
Pro now: $1 first month
What runs behind every stock
26
valuation models
8 families, DCF to NCAV
37
quality factors
margins, balance sheet, cashflow, debt
6
AI factors
moat, what no ratio measures
2,000+
data points
verified, per stock, median
69 individual criteria per stock, every one traceable See the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 23, 2026.
How to read this chart
60‑month range $59.07 – $148.95 · fair‑value band $25.06 – $42.31 · the $91.00 price screens above the $33.77 fair value. Dashed = 300-day average. As of Sep 23, 2026.
Company profile
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide.
Show more
Bachem Holding AG, together with its subsidiaries, provides products for research, clinical development, and commercial application to pharmaceutical and biotechnology companies worldwide. It engages in the development, production, and regulatory support of peptide active pharmaceutical ingredients, such as peptide and oligonucleotide new chemical entities (NCEs). The company also offers commercial NCEs and generics; and project management, quality and regulatory, analytical, good manufacturing practice production, research grade production, and supply and vertical integration services. Bachem Holding AG was incorporated in 1971 and is headquartered in Bubendorf, Switzerland. Bachem Holding AG operates as a subsidiary of Ingro Finanz AG.
Stock analysis
Bachem Holding (BCHMF) currently trades at $91.00, while our model-based Fair Value estimate is $33.77, 62.9% below the price, so the stock looks overvalued today.
Show more
Valuation
Bull case: the Growth Earnings group reads highest at a median of $35.50 per share, and 0 of the 16 models we run sit above the $91.00 price.
Bear case: the Dividend Discount group reads lowest at $7.49, and 16 of the 16 models stay below the price. Evidence for this calculation is high.
Scenario range: $25.06 (bear) to $42.31 (bull), the price of $91.00 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 57/100 (solid quality), in the Healthcare sector.
Expensive Growth: The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Bachem Holding reported revenue of CHF 695M in FY2025 versus CHF 503M in FY2021, a compound +8.4%/yr. Reported net income was CHF 149M in FY2025, compounding +6.7%/yr from FY2021.
Key figures
Market cap $6.8B · P/E ratio 36.4 · P/S ratio 7.79 · EPS (TTM) $2.50 · Dividend yield 1.0% · Net margin 21.4% · Return on equity 10.4% · Return on assets (EBIT) 8.2%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 50 out of 100 (low confidence).
What moves the price
The share trades about 2% below its 52-week high and 53% above its 52-week low, currently above its 200-day average.
For context, the median of 10 Healthcare peers we cover trades at 10% fair-value upside, at −63%, BCHMF screens richer than that median.
Fair Value models
The price assumes far more growth than our models allow for, so the models scatter widely ($7.49 to $63.77). Read the Fair Value as a cautious anchor, not a price target; the Growth Forecast section shows what the price assumes.
Bear $25.06
Fair Value $33.77
Bull $42.31
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Based on fiscal year 2025 figures (about 9 months old). Earnings retained since then ($1.21 per share) are deliberately not added.
Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds.
Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
Residual Income
$20.51
$22.67
$28.98
76
EPV
$20.31
$23.44
$26.14
74
ROIC Compounder
$20.31
$23.44
$29.82
72
All 16 models by family
Earnings-Based
Graham-Dodd
$16.31
$63.77
$86.54
64
Lynch FV
$15.69
$22.42
$29.15
61
PEG = 1.0
$15.69
$22.42
$29.15
57
EPV
$20.31
$23.44
$26.14
74
Dividend Discount
Gordon GGM
$4.35
$8.67
$13.12
67
DDM Multi-Stage
$4.35
$7.49
$9.15
67
Multiples
P/E Multiple
$30.57
$40.76
$50.95
63
P/S Multiple
$12.60
$16.80
$21.00
58
P/B Multiple
$30.57
$40.76
$50.95
55
EV/EBIT
$25.93
$34.41
$42.88
66
EV/EBITDA
$23.45
$31.10
$38.75
67
EV/Revenue
$12.26
$17.30
$22.34
54
Asset-Based
NCAV (Graham)
$11.75
$15.75
$23.50
54
Economic Profit
Residual Income
$20.51
$22.67
$28.98
76
ROIC Compounder
$20.31
$23.44
$29.82
72
Growth Earnings
Growth-Adj P/E
$24.85
$35.50
$46.15
67
Notify me when BCHMF reaches fair value
Put BCHMF on your watchlist. We get in touch as soon as price and fair value meet or the trend turns.
Set up alert →Quality Score breakdown
Overall quality
57/100
Of which business quality 56 · Market factors (momentum, volatility) 79
Profitability
43
Margins and returns on capital today
Quality Growth
49
Are margins and returns improving?
Cashflow
47
Earnings quality: real cash, not paper profit
Fin. Strength
81
Balance sheet, leverage, solvency risk
Investment
29
Disciplined investing over empire-building
Low Volatility
65
Calm price path (market factor)
Momentum
80
Price trend over the last 3–12 months (market factor)
52W Momentum
92
Distance to the 52-week high (market factor)
Net Issuance
81
Share count: buybacks or dilution?
Revenue & earnings trend
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.
52/100
The company is growing, but growth may require heavy reinvestment or weak cash conversion.
Revenue growth 1 year
+14.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+9.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+11.6%
Start year 2020 (pandemic). Over 10 years: +12.8% a year
Revenue growth 23 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.9%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
What shareholders gained per year (last 5 years) ⓘWhat the business itself delivers per year: earnings growth per share plus the dividend yield. This is what you get IF the market keeps valuing the stock the same way: it contains no assumption about the market changing its mind. Computed per share, so buybacks count and a merger does not pass as growth. For a company that pays no dividend it is pure earnings growth per share. Period: earnings growth per share as CAGR over the last 5 reported fiscal years (annual statements), plus the current dividend yield. The start value is the median of the three years around the start, so a single crisis year (a pandemic or a write-down) does not distort the rate.
+13.2%
Earnings growth per share plus dividend.
Earnings per share, growth per year+12.2%
Dividend (yield on the price)1.0%
Pace: 5 vs 10 years ⓘTwo data points, not a trend model: earnings growth per share over the last 5 fiscal years against the last 10. Labelled "steady" when both rates are within 3 percentage points of each other, otherwise picking up or flattening. Shown only when ten years of history exist.12.2% vs 15.5%, slowing
Profit margin 2020 to 2025 ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.24% → 22%
Start year 2020 (pandemic)
Earlier news
News mood ⓘNews mood, the average tone of recent news (28 articles), rated against how stocks are usually covered. 🚀 Hype = unusually upbeat · 🙂 Positive = above average · 😐 Neutral = typical · 🙁 Negative = below average · 😨 Very negative = unusually downbeat. It reflects the tone of coverage, not our valuation.
Hype
Recent news coverage is unusually upbeat, far more positive than stocks are typically covered.
- Bachem Holding AG (BCHMF) (H1 2026) Earnings Call Highlights: Strategic Expansion and Refined ...
- Bachem Confirms Growth and Expects a Strong Second Half 2026
- Bachem Plans to Build a Large-Scale Production Facility in Sisslerfeld
- Bachem Holding (SWX:BANB) Stock Valuation Check After Recent Share Price Pullback
Compare Bachem Holding with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Biotechnology · 625 stocks
Beats the industry median on 6/12 measures
A mixed picture versus its industry peers.
Valuation Multiplesvs Biotechnology median · lower = cheaper
Context: sector, industry, market
- Is the Materials sector expensive or cheap?
- P/E, EV/EBITDA and margins by industry (reference tables)
- Undervalued stocks: US Stocks
- Valuation of the USA market
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
None of the checked exposures detected
Similar stocks
10 more Biotechnology stocks, each showing price versus our Fair Value estimate.
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Vertex Pharmaceuticals Incorporated VRTX | $527.67 | $580.44 | +10% |
| Regeneron Pharmaceuticals, Inc REGN | $752.25 | $1,275 | +69% |
| argenx SE ARGX | $959.49 | $918.60 | −4% |
| CSL Limited CSL | A$175.35 | A$192.89 | +10% |
| Samsung Biologics Co 207940 | 1,354,000 KRW | 1,489,400 KRW | +10% |
| BeOne Medicines AG ONC | $360.85 | $280.94 | −22% |
| Alnylam Pharmaceuticals, Inc ALNY | $255.96 | $217.88 | −15% |
| Royalty Pharma plc RPRX | $58.21 | $19.01 | −67% |
| Celltrion, Inc 068270 | 177,400 KRW | 74,519 KRW | −58% |
| WuXi Biologics (Cayman) Inc 2269 | HK$53.00 | HK$58.30 | +10% |
Explore undervalued stocks
More undervalued Healthcare stocks →
All undervalued stocks
TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks
Try a ready-made strategy
Pick a strategy and jump into the live analysis with that exact screen applied.
🥇 Backtested Best
🏆 Big Names
⭐ Top Rated
💎 Quality on Sale
🚀 Profitable Growth
🧊 Quality Compounders
💵 Dividend Stars
📈 Strong Momentum
📉 Fallen Angels
⚖️ Deeply Undervalued
🔍 Small-Cap Gems
🏰 Moat at a Fair Price
💼 Insider Buying
🎩 Buffett-Style Quality
📚 Peter Lynch GARP
🧮 Greenblatt Magic Formula
🛡️ Graham Defensive
Discover tools
Stock screenerFilter by region, size and sector
Compare toolTwo stocks side by side
Extrinsic Value Calculator…Calculator with industry benchmark
Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
Frequently asked questions
Is Bachem Holding (BCHMF) overvalued or undervalued?
As of Sep 23, 2026, our model estimates a fair value of $33.77 versus the last price from Sep 25, 2026 of $91.00, about −63% upside (overvalued).
What is the fair value of BCHMF?
Our model-based fair value for Bachem Holding is $33.77 (as of Sep 23, 2026), built from audited fundamentals. Last price (from Sep 25, 2026): $91.00.
What is the quality score of BCHMF?
Bachem Holding has a Quality Score of 57/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Bachem Holding (BCHMF)?
Our model-based price target is the fair value of $33.77 (as of Sep 23, 2026) from 16 valuation models. Cautious scenario $25.06, optimistic scenario $42.31. It is a calculation from audited fundamentals, not an analyst target.
What is the Bachem Holding stock forecast for 2026?
Our models put fair value at $33.77, about −63% upside versus the last price from Sep 25, 2026 of $91.00 (overvalued). Cautious scenario $25.06, optimistic scenario $42.31. The calculation is refreshed regularly with new filings.
What is the revenue of Bachem Holding (BCHMF)?
Bachem Holding reported trailing-twelve-month revenue of about CHF 695M (latest available figure, as of Sep 23, 2026).
Does Bachem Holding pay a dividend?
Bachem Holding currently shows a dividend yield of about 0.99% relative to its recent price (as of Sep 23, 2026).
What is the intrinsic value of Bachem Holding (BCHMF)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Bachem Holding it is $33.77 per share (as of Sep 23, 2026), against a price of $91.00. It is the blended result of 16 valuation models (cash flow, earnings, asset, dividend).
Is Bachem Holding stock overvalued or undervalued in 2026?
As of Sep 23, 2026, BCHMF trades above its calculated fair value: price $91.00, fair value $33.77, a gap of about −63% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of BCHMF?
No. The price is what the market pays today ($91.00); the fair value is what the company's own numbers justify ($33.77). For Bachem Holding the two are $57.23 per share apart. That gap is exactly why we show both numbers side by side.
How much is Bachem Holding worth?
The market values Bachem Holding at about $6.8B (market capitalisation, as of Sep 23, 2026). Per share that is $91.00; our models calculate a fair value of $33.77 per share.
What do the bullish and bearish scenarios say about BCHMF?
Our models span a range for Bachem Holding: cautious scenario $25.06, base $33.77, optimistic $42.31 per share (as of Sep 23, 2026, price $91.00). The range comes from different growth and margin assumptions, not from analyst opinions.
What is the P/E ratio of BCHMF?
Bachem Holding trades at a price-to-earnings ratio of 36.4 (as of Sep 23, 2026). A P/E on its own says little: it compares the price with ONE year of profit, while our fair value of $33.77 is built from several models across several years. Other multiples: P/B 4.5, P/S 9.4, EV/EBITDA 30.9.
How solid is the balance sheet of Bachem Holding (BCHMF)?
Balance-sheet figures for Bachem Holding (as of Sep 23, 2026): return on equity 10.4%. They feed the Quality Score of 57/100, which measures business quality independently of the share price.
How far is BCHMF from its 52-week high?
Bachem Holding trades at $91.00, about 2% below its 52-week high of $92.81 and 53% above the low of $59.35 (as of Sep 25, 2026). Distance from the high says nothing about value: that is what the fair value of $33.77 is for.
Which stocks are comparable to Bachem Holding?
From the same area (Healthcare) we also value Vertex Pharmaceuticals Incorporated, Regeneron Pharmaceuticals, Inc, argenx SE, CSL Limited, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Bachem Holding stock attractive at the current price?
The data as of Sep 23, 2026: price $91.00, calculated fair value $33.77 (−63%), Quality Score 57/100, from 16 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of BCHMF calculated?
We run Bachem Holding through 16 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of $33.77, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.5 % above its aggregate fair value. Bachem Holding itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Bachem Holding (BCHMF)?
The latest price we hold is from Sep 25, 2026 and stands at $91.00. Our model-based fair value is $33.77, about −63% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Bachem Holding right now?
The price sits above even our optimistic bull case ($42.31). The favourable scenario is already priced in. Solid but not exceptional quality (57/100) and above fair value, neither a clear bargain nor a standout compounder.
Where does the earnings growth of Bachem Holding (BCHMF) come from?
Earnings per share at Bachem Holding grew +14.4 % a year from 2014 to 2025. Broken into its drivers: revenue per share +11.6 %, EBIT margin +1.6 %, tax rate +0.8 %, residual (interest, one-offs) +0.1 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Bachem Holding
How large is the market capitalisation of Bachem Holding (BCHMF)?
The market capitalisation of Bachem Holding is $6.8B. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Bachem Holding (BCHMF)?
The price-to-sales ratio of Bachem Holding is 7.79 (P/E × margin). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Bachem Holding (BCHMF)?
Earnings per share at Bachem Holding are $2.50 (price ÷ EPS = P/E 36.4). Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Bachem Holding (BCHMF)?
The dividend yield of Bachem Holding is 1.0% (payout 36.0%). Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Bachem Holding (BCHMF)?
The net margin of Bachem Holding is 21.4% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Bachem Holding (BCHMF)?
The return on equity (ROE) of Bachem Holding is 10.4% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Bachem Holding (BCHMF)?
On an EBIT basis the return on assets of Bachem Holding is 8.2% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Bachem Holding (BCHMF)?
The operating margin of Bachem Holding is 26.3% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Bachem Holding (BCHMF)?
Revenue at Bachem Holding is growing +4.7% versus a year earlier (3y avg +9.4%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Bachem Holding (BCHMF)?
Earnings per share at Bachem Holding are growing +16.6% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Bachem Holding (BCHMF) generate?
The free cash flow of Bachem Holding is −CHF 48.2M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Bachem Holding (BCHMF) carry?
The net debt of Bachem Holding is CHF 26.4M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Bachem Holding in the live analysis
One click puts Bachem Holding on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
Watch for free →Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.